

Special Issue

Personalized Therapy and Clinical Outcomes for Heart Failure

Message from the Guest Editor

This Special Issue focuses on the integration of personalized approaches into the management of both acute and chronic heart failure. We aim to showcase research that advances phenotyping, risk stratification, biomarkers, imaging, genetics, and treatment optimization. Cutting-edge contributions on novel therapeutic targets, digital health tools, and real-world clinical outcomes are particularly encouraged.


Guest Editor

Dr. Gonzalo Luis Alonso Salinas

1. Cardiology Department, Hospital Universitario de Navarra, 31006 Pamplona, Spain
2. Health Sciences Department, Universidad Publica de Navarra (UPNA), 31006 Pamplona, Spain

Deadline for manuscript submissions

25 November 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/266347

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).